HUM · Humana Inc. · Stock research

Current Thesis

The shelf that gave way on 2026-08-04 was rebuilt inside three sessions. HUM traded down to $353.69 intraday on 2026-08-05 — through the $355.81 print-day low of 2026-07-29 — and closed green at $363.82. That happened on the morning CVS Health reported Q2 adjusted EPS of $2.58 against a $1.85 consensus, an Aetna medical benefit ratio of 87.4% versus 89.9% a year earlier, and raised FY2026 adjusted EPS guidance to $7.90–$8.10 from $7.30–$7.50. The peer comparison that took 5.99% out of HUM on 2026-07-29 was re-run with a stronger Aetna number and the stock closed up 0.46%.

From there: 2026-08-06 close $367.24 (+0.94%), 2026-08-07 close $385.00 (+4.84%), the highest close since the 2026-07-28 close of $388.71 and back above the 50-day of $374.23. No Humana press release is dated to the 08-06 or 08-07 sessions on the company newswire; the only August company items are an iCare Wisconsin contract award (2026-08-05) and a volunteer event scheduled for 2026-08-26.

The narrative leg on offer has not changed: a sustainable pre-tax Medicare Advantage margin of "at least 3% in 2028," reaffirmed on the 2026-07-29 call, with no published 2027 EPS or margin figure bridging to it. What changed is who is underwriting it. On 2026-08-05 Morgan Stanley moved to Equal-Weight from Underweight and lifted its target to $370 from $249, citing in-line cost trends for both new and existing MA cohorts and a better-than-expected new-member experience tracking the 2028 bridge from the 2025 Investor Day. The $249 anchor at the bottom of the target distribution is gone.

Bullish and bearish views on Humana Inc.

The model's bull view on Humana Inc. (HUM), in brief: The post-print low was undercut and rejected. The bear view: The cost gap to Aetna is the whole 2028 story and no 2026 number narrows it. Both cases follow in full.

Bull Case

• The post-print low was undercut and rejected. 2026-08-05 low $353.69 versus the 2026-07-29 print-day low of $355.81; the session closed $363.82, and the two sessions after it closed higher (stockanalysis.com daily OHLC through 2026-08-07).
• The peer cost-trend bar came in and HUM did not derate against it. CVS reported an Aetna MBR of 87.4% (from 89.9%), revenue $106.1B, and raised FY2026 adjusted EPS to $7.90–$8.10 with a FY2026 MBR guide of 89.75% ±25bps (CVS Q2 2026 release, 2026-08-05). A turning MA cost cycle is the same cycle Humana's 2028 target depends on.
• The last major-broker bear capitulated. Morgan Stanley Underweight → Equal-Weight, PT $249 → $370, 2026-08-05, on evidence that new MA cohorts are not developing worse than assumed.
• Q2 2026 cleared both lines. Adjusted EPS $7.61 vs $7.22 consensus on revenue $40.888B vs $40.611B; FY2026 adjusted EPS guided to at least $9.00 vs $8.94 consensus; the FY2026 insurance benefit-ratio guide of 92.75% ±25bps was not widened (8-K and Form 10-Q, 2026-07-29).
• Targets sit above the market. BofA Buy $500 (2026-07-30), Evercore ISI Outperform $480, Guggenheim Buy $471, Piper Sandler Overweight $463 (from $254); consensus average target $415.25 (finviz, 2026-07-31) against the 2026-08-07 close of $385.00.
• The primary trend is intact. 200-day moving average $267.78 as of 2026-08-09, more than 115 points under the 08-07 close; 2026-06-03 base close $327.54.
• The book grew while being pruned. 17.9M total members at 2026-06-30, roughly 7.2M in MA against about 5.8M a year earlier; individual MA +23%, PDP +63%; CenterWell revenue up about 32%.

Bear Case

• The cost gap to Aetna is the whole 2028 story and no 2026 number narrows it. Humana's FY2026 insurance benefit-ratio guide is 92.75% ±25bps; CVS guided its Health Care Benefits MBR to 89.75% ±25bps on 2026-08-05. The books are not mix-comparable — Humana is overwhelmingly government-funded — but the direction of the spread is what the sell-side is extrapolating away.
• Star Ratings remain the unhedged exposure. 20% of Humana's MA members are in 4-star-plus plans on the 2026 ratings, down from 94% on the 2024 ratings; Aetna reports over 81% (CMS 2026 Star Ratings; Healthcare Dive 2025-10-02). The October 2026 release governs plan-year-2028 bonus revenue.
• The upgrade cycle is close to spent. Eight revisions landed 2026-07-30/07-31 and Morgan Stanley followed on 08-05 — but Morgan Stanley's new $370 target is below the 08-07 close of $385.00, and TD Cowen Hold $370, UBS Neutral $405 and Barclays Equal-Weight $407 are all at or under where the stock now trades. Raymond James cut to Market Perform on 2026-07-30.

• The GAAP guide was cut and not restored. FY2026 GAAP EPS guided to more than $6.52 against $8.55 consensus (2026-07-29).
• The 2027 base is being deliberately shrunk. Roughly 600,000 members sit in exited 2027 plans, about 8% of the 7.2M MA base, the majority rated 3.5 stars or lower for the 2027 bonus year, with management expecting to retain just over 40% (Q2 call, 2026-07-29).
• Part D economics reset next year. CMS set the CY2027 national average monthly bid at $296.05, up 24%, the base beneficiary premium at $41.33, and confirmed the Part D Premium Stabilization Demonstration ends after CY2026 (CMS fact sheet, 2026-07-28) — into a PDP book that grew 63% year over year.
• Valuation carries the recovery already. Forward P/E 31.22 as of 2026-08-09 on depressed earnings, with no 2027 anchor published.

Setup & Price Structure

The post-print range now has three defined edges. Floor: $353.69 (08-05 low) / $355.71 (08-06 low) / $355.81 (07-29 low) — a three-print band that has been probed and held. Mid: the 50-day at $374.23, lost on 08-04, reclaimed on 08-07. Overhead: the 07-28 close of $388.71, then the highest close of the 2026 advance, $407.78 on 2026-07-15, and the $428.88 intraday high of 2026-07-16. Below everything, the 2026-06-03 base close of $327.54.

Life-cycle: MATURING. The managed-care recovery theme has been running since the 2026-04-07 CMS rate notice (HUM +9%, UNH +11% intraday per 24/7 Wall St) and the 2026-06-04 cost-trend session (HUM +6%, UNH +5%, CI +4%, same source). It is still working — 08-07 made the highest close in eight sessions — but the flow is moderating rather than expanding: the sell-side conversion completed on 2026-08-05 when the last major Underweight went to Equal-Weight, and the strongest up day since the print printed the lightest volume of the week. Coverage is now trade-press standard rather than novel. What would date a flip to SATURATED is targets continuing to rise while price fails to reclaim $388.71 and $407.78.

no squeeze fuel. Beta 0.74. Consensus rating Buy with an average target of $415.25 (finviz, 2026-07-31), so the 08-07 close sits inside the target cloud rather than beneath it. Nine broker actions in seven sessions (07-30 through 08-05) is a dense revision cluster. No earnings date falls inside 30 days, and no insider transactions appear on the recent-filings feed for the period since the 2026-07-29 print.

Catalyst Calendar (next 30 days)

• 2026-08-26 — Humana Community Day, a company-scheduled nationwide volunteer event. Non-financial; it resolves nothing about margin or enrollment. It is the only company-dated item inside the window.
• ~2026-09-09 (est., unconfirmed) — Wells Fargo Healthcare Conference. Humana's CFO presented on 2024-09-04 and 2023-09-06 in prior years; no 2026 appearance is posted on the company's events calendar as of 2026-08-09.
• Immediately beyond the window: ~2026-09-25 (est.) CMS 2027 MA and Part D landscape files; ~2026-09-30 (est.) Annual Notice of Change letters; ~2026-10-08 (est.) 2027 Star Ratings; 2026-10-15 Annual Enrollment Period opens; ~2026-11-04 (est.) Q3 print.

The practical read: roughly 47 days separate 2026-08-09 from the first disclosure that can be checked against management's claims.

Elapsed catalysts

• Unscheduled, can land in any session — Fifth Circuit ruling in No. 25-11293, the Star Ratings appeal. Noticed 2025-11-25; defendants' opening brief filed 2026-03-21; no argument or decision date on the public docket. (passed 141d ago)

What Would Change Our Mind

The reclaim is three sessions old and rests on a floor that has been tested exactly once. Losing that floor is the structural break: a daily close below $353 takes out the 08-05 low of $353.69 and the 07-29 print-day low of $355.81 together, which would make the 08-05 undercut a failed reversal rather than a base. Below that, a weekly close below $327 unwinds the entire leg off the 2026-06-03 base close of $327.54.

The non-price conditions that would break the frame independently: the ~October 2026 Star Ratings leaving 4-star-plus enrollment near the 20% of the 2026 ratings, which impairs 2028 bonus revenue in the same year management has promised a 3% margin; a Q3 print on ~2026-11-04 that again declines to put a number on 2027; or an insurance benefit ratio printing above the 92.75% ±25bps FY2026 guide. On the other side, the September landscape files showing the ~600,000 exited members concentrated in 3.5-star-and-below plans as described would convert a management assertion into a filed fact.

Correlation Notes

HUM trades on the Medicare Advantage policy-and-cost-trend factor, not the index — beta 0.74. The complex moves together on CMS dates and peer prints: 2026-04-07 rate notice (HUM +9%, UNH +11% intraday, 24/7 Wall St), 2026-06-04 softer cost trends (HUM +6%, UNH +5%, CI +4%), and mid-July 2026 on UnitedHealth's FY2026 guide raise to $19.50–$20.00 adjusted EPS (HUM up almost 5%, ELV +2.5%, per Investing.com).

The dispersion is where the idiosyncratic risk sits. On 2026-08-04 HUM fell 3.30% against UNH −1.88%, ELV −1.25% and CVS −0.90% with no Humana-dated headline. On 2026-08-05 the direction reversed on a competitor's beat. Star Ratings is the one factor with no peer offset: 20% of Humana MA members in 4-star-plus 2026 plans against Aetna's 81%-plus means a good sector tape and a bad October are fully compatible. CenterWell ties a second thread to provider and home-health economics, which do not co-move with the payer complex on rate-notice days.